Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

1.25USD
15 Dec 2017
Change (% chg)

$-0.05 (-3.85%)
Prev Close
$1.30
Open
$1.30
Day's High
$1.30
Day's Low
$1.25
Volume
35,047
Avg. Vol
37,755
52-wk High
$2.92
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Affimed reports Q3 loss per share EUR 0.18
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.  Full Article

Affimed announces Q3 financial results and corporate update conference call
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.  Full Article

Affimed Q2 loss per share EUR 0.24
Wednesday, 10 Aug 2016 

Affimed Nv : Affimed reports financial results for second quarter 2016 and provides corporate update . Q2 earnings per share view eur -0.20 -- Thomson Reuters I/B/E/S . Q2 loss per share eur 0.24 .Q2 revenue eur 2.1 million versus i/b/e/s view eur 1.9 million.  Full Article

Affimed Q1 loss per share Eur 0.25
Wednesday, 18 May 2016 

Affimed NV : Affimed reports financial results for first quarter 2016 . Q1 loss per share eur 0.25 . Q1 revenue eur 1.9 million versus i/b/e/s view eur 1.9 million .Q1 earnings per share view eur -0.17 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash